Medicare will save approximately $12 billion, or 44%, on 15 high-cost medications as a result of the second round of the program’s drug price negotiations, the Trump administration announced Tuesday ...

Major stock indexes ended sharply higher Monday to begin a holiday-shortened trading week, with investors increasingly confident the Federal Reserve will cut interest rates at its December meeting.

The U.S. government announced it has negotiated a 71% discount on Novo Nordisk’s (NVO) Ozempic and Wegovy drugs for patients in Medicare, ...

The US government said it negotiated a 71% discount on Novo Nordisk A/S’s blockbuster Ozempic and Wegovy drugs for patients ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

Background: In January, Greystar was named as a defendant in an antitrust lawsuit filed by California Attorney General Rob ...

Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...

Medicare will announce negotiated prices for 15 high-cost drugs, impacting over 67 million beneficiaries. The Inflation ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of blockbuster drugs Ozempic and Wegovy, but scientists are still asking if GLP-1 drugs ...

Vascular dementia is the second-most common form of dementia after Alzheimer's. About 2.7 million people in the U.S. are thought to have mixed dementia or vascular dementia, which is caused by strokes ...

A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer's disease, drugmaker Novo Nordisk announced on Nov. 24.

While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.